Neumora Therapeutics has raised $112m in a Series B financing round to advance its new precision medicine candidates pipeline for neuropsychiatric disorders and neurodegenerative diseases.
New and existing investors including F-Prime Capital, Altitude Life Science Ventures, Mubadala Capital, Amgen, Exor Ventures, ARCH Venture Partners, Invus, Abu Dhabi Growth Fund (ADG), Newpath Partners, Polaris Partners, as well as other undisclosed investors have participated in the financing round.
Neumora has raised nearly $650m in capital to date.
The company also intends to use the funding to develop its precision neuroscience platform.
Recently, it completed subject enrolment in a Phase IIa clinical trial of NMRA-140, which is a kappa opioid receptor antagonist in development to treat the major depressive disorder.
Next year, Neumora plans to advance the clinical-stage vasopressin 1a receptor antagonist, NMRA-511, and an M4 muscarinic receptor-positive allosteric modulator, NMRA-266, into Phase I development for schizophrenia.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Neumora co-founder, chairman and CEO Paul Berns said: “This Series B financing reflects Neumora’s continued progress in building a best-in-class neuroscience company, including assembling a world-class team, scaling up an industry-leading data science and translational neuroscience platform, and advancing a broad and growing pipeline of seven development programs, including our internal discovery efforts and business development activities.
“This considerable amount of progress in such a short period of time reflects our urgency to address the relative lack of progress and innovation in neuroscience with our data-driven, precision medicine approach.”
The company’s earlier-stage pipeline includes several preclinical candidates’ development, including neurodegeneration programmes which are focused on Parkinson’s disease and amyotrophic lateral sclerosis (ALS).